🇺🇸 FDA

P1 · Therapeutic area intelligence

Oncology patent intelligence

Anticancer agents, immuno-oncology, ADC, and oncology patent filings — grants, expirations, and assignee activity.

Patents
1,930

Quick answer

1,930 US pharmaceutical patents in our index match Oncology title keywords (A61K/A61P). Cross-link to related drug therapeutic-area hubs and company patent portfolios for full IP context.

  1. US 10532109

    Peptide-DNA chimeras for treatment of HER overexpressing cancers

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Tue Jan 14 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10533040

    Colon and pancreas cancer peptidomimetics

    PRECISION BIOLOGICS, INC. · Granted Tue Jan 14 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10533056

    Macropinocytosing human anti-CD46 antibodies and targeted cancer therapeutics

    The Regents of the University of California · Granted Tue Jan 14 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10533227

    Compositions, kits, and methods for identification, assessment, prevention and therapy of breast and ovarian cancer

    The Board of Regents of the University of Texas System · Granted Tue Jan 14 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10532040

    Methods of treating cancer with herbacetin

    Regents of the University of Minnesota · Granted Tue Jan 14 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10526414

    Use of anti-semaphorin-4D antibodies in combination with an immune modulating therapy to inhibit tumor growth and metastases

    VACCINEX, INC. · Granted Tue Jan 07 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10525104

    Predictive and prognostic biomarkers related to anti-angiogenic therapy of metastatic colorectal cancer

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 07 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10517894

    Restimulation of cryopreserved tumor infiltrating lymphocytes

    Iovance Biotherapeutics, Inc. · Granted Tue Dec 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10517948

    Anti-DC-HIL antibodies for cancer diagnosis, prognosis and therapy

    The Board of Regents of the University of Texas System · Granted Tue Dec 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10519247

    Targeting HER2 and HER3 with bispecific antibodies in cancerous cells

    The Board of Regents of the University of Texas System · Granted Tue Dec 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10512630

    Compositions and methods for treating cancer

    The Regents of the University of California · Granted Tue Dec 24 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10500277

    Combination tumor treatment with drug-loaded, bispecific ligand-targeted minicells and interferon-gamma

    EnGeneIC Molecular Delivery Pty Ltd · Granted Tue Dec 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10501800

    Breast cancer prognosis

    Regents of the University of Minnesota · Granted Tue Dec 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10501428

    Thymoquinone derivatives for treatment of cancer

    UNITED ARAB EMIRATES UNIVERSITY · Granted Tue Dec 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10500271

    Compositions and methods for self-adjuvanting vaccines against microbes and tumors

    The Regents of the University of California · Granted Tue Dec 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10501801

    Identification of tumor-protective epitopes for the treatment of cancers

    UNIVERSITY OF CONNECTICUT · Granted Tue Dec 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10500175

    Compositions and methods for the treatment of cancer

    KoDiscovery, LLC · Granted Tue Dec 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10501538

    Anti-LILRB antibodies and their use in detecting and treating cancer

    The Board of Regents of the University of Texas System · Granted Tue Dec 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10500290

    Peptide reagents and methods for detection and targeting of dysplasia, early cancer and cancer

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Dec 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10493162

    Somatostatin receptor-based cancer therapy

    The Board of Regents of the University of Texas System · Granted Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10488416

    Targeting breast cancer therapy based on stromal subtypes and CD146 composition

    The Regents of the University of Colorado, a Body Corporate · Granted Tue Nov 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10485792

    Sustained release delivery systems for the prevention and treatment of head and neck cancers

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Nov 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10479839

    Internalizing human monoclonal antibodies targeting prostate cancer cells in situ

    The Regents of the University of California · Granted Tue Nov 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10471144

    Combination of local rose bengal and systemic immunomodulative therapies for enhanced treatment of cancer

    Provectus Pharmatech, Inc. · Granted Tue Nov 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10471051

    Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer

    Asana BioSciences, LLC · Granted Tue Nov 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10471055

    Methods of treating cancer patients with farnesyltransferase inhibitors

    Kura Oncology, Inc. · Granted Tue Nov 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10465004

    Frizzled receptor antibodies for treatment of cancer

    TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD. · Granted Tue Nov 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10463697

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Tue Nov 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10463734

    Nanoparticle therapy in cancer

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Nov 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10463654

    Combination therapies for treating cancer

    RedHill Biopharma Ltd. · Granted Tue Nov 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10457662

    Substituted amides for treating and preventing cancer

    The Board of Regents of the University of Texas System · Granted Tue Oct 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10457725

    Methods of treating skin cancer by administering a PD-1 inhibitor

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10457726

    Antibody and antigen-binding fragment compositions targeting cell surface antigens in tumors and methods of use thereof

    UNIVERSITY OF CONNECTICUT · Granted Tue Oct 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10457676

    Capsazepine analogs for the treatment of cancer and other proliferative diseases

    The Board of Regents of the University of Texas System · Granted Tue Oct 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10449191

    Treatment of prostate cancer

    Takeda Pharmaceutical Company Limited · Granted Tue Oct 22 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10450275

    Compounds and methods for treating cancer, neurological disorders, ethanol withdrawal, anxiety, depression, and neuropathic pain

    The Board of Regents of the University of Texas System · Granted Tue Oct 22 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10449178

    Glucocorticoid receptor modulators to treat pancreatic cancer

    Corcept Therapeutics Incorporated · Granted Tue Oct 22 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10448637

    Inhibitors of GRB2-associated binding protein 1 (GAB1) and methods of treating cancer using the same

    Arizona Board of Regents on Behalf of the University of Arizona · Granted Tue Oct 22 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 10444237

    Anti-pancreatic cancer monoclonal antibody and use thereof

    NANJING MARKERLINE BIOMEDICAL TECHNOLOGY CO., LTD. · Granted Tue Oct 15 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10441645

    MSLN targeting DNA vaccine for cancer immunotherapy

    Vaximm AG · Granted Tue Oct 15 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10441663

    Methods for treating cancer

    BicycleRD Limited · Granted Tue Oct 15 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10434174

    Combination therapies using platinum agents and agents that target tumor-associated stroma or tumor cells

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Oct 08 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10434075

    FKBP52 specific androgen receptor inhibitor, MJC13, for use in treating breast cancer

    The Board of Regents of the University of Texas System · Granted Tue Oct 08 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 10426797

    Compositions and methods for treating cancer with anti-CD33 immunotherapy

    United State of America, As Represented by the Secretary, Dept. of Health and Human Services · Granted Tue Oct 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 10428132

    Tumor necrosis factor-related apoptosis-inducing ligand variant, as well as a preparation method and use thereof

    WEST CHINA HOSPITAL, SICHUAN UNIVERSITY · Granted Tue Oct 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 10426767

    Methods of treating cancer with farnesyltransferase inhibitors

    Kura Oncolofy, Inc. · Granted Tue Oct 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 10420799

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Tue Sep 24 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 10421945

    Agents and methods to elicit anti-tumor immune response

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Sep 24 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many Oncology patents are indexed?

1,930 patents match our Oncology classifier (title keywords in USPTO records).

Is this legal or medical advice?

No — patent intelligence is for professional reference. Verify expiration and FTO with qualified patent counsel and primary USPTO records.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.